Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioWa and Medarex have signed a license agreement which provides Medarex with the first ever access to BioWa's Complegent technology for enhancing the complement-dependent cytotoxicity of select Medarex therapeutic antibodies.
Subscribe to our email newsletter
The license grants Medarex non-exclusive rights to research, develop and commercialize therapeutic antibodies based on Complegent technology for an undisclosed number of targets.
In return, BioWa will receive upfront payment, license fees, development milestone payments and royalties on products.
Howard Pien, president and CEO of Medarex, said: “We are excited about the possibility of enhancing our antibodies with BioWa’s technology platform. Our partnership grants Medarex the first access to Complegent technology and we look forward to investigating its potential as we continue to advance our pipeline.”